Elite Pharmaceuticals Inc (ELTP)

[Moose45]

I emailed the Abuse Deterrent Coalition on ELI-200. This was their response:

HI Craig,

Thanks for your note. ELI-200 is designed as a long acting opioid, using and agonist-antagonist ADF formulation – naltrexone combined with the active pain relief opioid. The AD Coalition supports Elite Pharma’s efforts to bring its product through clinical trials and ultimately to the market with an ADF formulation designed to deter abuse. Like you, we will watch for the results of the current Phase III efficacy trial and look forward to learning about the data.